PTC Therapeutics (PTCT) Tops Q2 EPS by 13c; Offers FY16 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to PTC Therapeutics (PTCT) Tops Q2 EPS by 13c; Offers FY16 Outlook

PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update

August 4, 2016 4:05 PM EDT

SOUTH PLAINFIELD, N.J., Aug. 4, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2016.

"Making Translarna available to all Duchenne muscular dystrophy patients globally who may benefit continues to be our top priority," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc.  "Global sales are on a strong growth trajectory as we continue to expand access outside of the U.S. We are excited patients in England can now access reimbursed Translarna and have... More